Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$531 Mln
P/E Ratio
--
P/B Ratio
0.9
Industry P/E
--
Debt to Equity
0.03
ROE
-0.41 %
ROCE
-39.99 %
Div. Yield
0 %
Book Value
15.45
EPS
-5.06
CFO
$-302.57 Mln
EBITDA
$-384.83 Mln
Net Profit
$-375.46 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Keros Therapeutics Inc (KROS)
| -11.12 | 21.50 | 33.75 | -75.74 | -39.84 | -12.30 | -- |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
|
|---|---|---|---|---|
|
Keros Therapeutics Inc (KROS)
| -59.89 | -17.20 | -17.93 | -17.05 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.19 | 10,226.85 | 20.76 | 23.13 | |
| 296.28 | 9,219.66 | 24.15 | 58.42 | |
| 24.72 | 10,361.50 | -- | -28.77 | |
| 101.38 | 9,388.25 | 28.84 | 14.16 |
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in... the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment neuromuscular diseases. The company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts. Address: 1050 Waltham Street, Lexington, MA, United States, 02421 Read more
President, CEO, Treasurer, & Director
Dr. Jasbir S. Seehra Ph.D.
President, CEO, Treasurer, & Director
Dr. Jasbir S. Seehra Ph.D.
Headquarters
Lexington, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Keros Therapeutics Inc (KROS) stood at $ 616 Mln as on 31-Dec-24
The share price of Keros Therapeutics Inc (KROS) is $14.07 (NASDAQ) as of 17-Apr-2025 16:00 EDT. Keros Therapeutics Inc (KROS) has given a return of -39.84% in the last 3 years.
Keros Therapeutics Inc (KROS) has a market capitalisation of $ 531 Mln as on 16-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Keros Therapeutics Inc (KROS) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Keros Therapeutics Inc (KROS) and enter the required number of quantities and click on buy to purchase the shares of Keros Therapeutics Inc (KROS).
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment neuromuscular diseases. The company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts. Address: 1050 Waltham Street, Lexington, MA, United States, 02421
The CEO & director of Dr. Jasbir S. Seehra Ph.D.. is Keros Therapeutics Inc (KROS), and CFO & Sr. VP is Dr. Jasbir S. Seehra Ph.D..
There is no promoter pledging in Keros Therapeutics Inc (KROS).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,031
|
|
|
989
|
|
|
950
|
|
|
915
|
| Keros Therapeutics Inc (KROS) | Ratios |
|---|---|
|
Return on equity(%)
|
-41.46
|
|
Operating margin(%)
|
-5269.1
|
|
Net Margin(%)
|
-5277.55
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Keros Therapeutics Inc (KROS) was $0 Mln.
$0.54
(
